WHO Experts' Group to take a call on EUL for Covaxin on October 6

The Strategic Advisory Group of Experts on Immunization of the WHO would be meeting in October to make its recommendations on Bharat Biotech's COVID-19 vaccine Covaxin on Emergency Use Listing

Bharat Biotech, Covaxin
Photo: Shutterstock
Press Trust of India Hyderabad
2 min read Last Updated : Sep 19 2021 | 10:47 AM IST

: The Strategic Advisory Group of Experts on Immunization (SAGE) of the World health Organisation would be meeting in October to make its recommendations on Bharat Biotech's COVID-19 vaccine Covaxin on Emergency Use Listing.

Bharat Biotech is expected to give a presentation on the Vaccine's safety and efficacy data of clinical trials (phase 1-3 trial results and post marketing)and Risk management plans and other implementation considerations, according to the SAGE draft agenda.

SAGE is authorised with advising WHO on overall global policies and strategies, ranging from vaccines and technology, research and development, to delivery of immunization and its linkages with other health interventions. Hanna Nohynek, member of SAGE, will be presenting a draft recommendation for the vaccine and the session will make its recommendations.

The session will thoroughly discuss the clinical data on Covaxin from phase 1, 2, 3 trials and post marketing studies on safety, immunogenicity, efficacy and effectiveness, besides update on global, regional and country level plans for vaccine safety monitoring, the agenda said.

Bharat Biotech recently said it has submitted all the data pertaining to Covaxin to the WHO for EUL and is awaiting feedback from the global health watchdog.

The WHO is currently reviewing the data submitted by the vaccine maker and the date for a decision on the jab is yet "to be confirmed," according to the update available on the WHO website.

In an update on its website, the WHO said it began rolling data of the vaccine on July 6. Rolling data allows the WHO to start its review right away, as information continues to come in, to accelerate the overall review process.

Covaxin is one of the six vaccines that have received emergency use authorisation from India's drug regulator and is being used in the nationwide inoculation programme, along with Covishield and Sputnik V.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :World Health OrganizationBharat BiotechCoronavirus Vaccine

First Published: Sep 19 2021 | 10:47 AM IST

Next Story